IV期黑色素瘤转移灶切除术后总生存期延长
基于美国国家癌症数据库2004-2015年IV期黑色素瘤病例,比较转移灶切除术与非手术患者的生存结局。转移灶切除术与更长的总生存期独立相关,在皮肤、肺和内脏转移亚组中均观察到生存获益。
要点
- IV期黑色素瘤转移灶切除与总生存期改善独立相关。
- 皮肤转移(M1a)患者术后中位生存46.36个月,未手术者15.31个月。
- 肺(M1b)和内脏(M1c)转移患者术后也显示生存获益。
核心结论
- IV期黑色素瘤转移灶切除术独立关联于改善的总生存期,涉及皮肤、肺和内脏转移。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2004-2015年IV期黑色素瘤病例,排除缺失治疗/分期数据或接受姑息治疗者后纳入14 034例。
- 患者分为转移灶切除术组(n=4214,30.0%)和非转移灶切除术组(n=9820,70.0%)。
- 使用Kaplan-Meier和Cox比例风险回归分析生存结局。
主要发现
- 单变量分析中,转移灶切除术组中位生存15.67个月,非手术组7.13个月(5年OS 13.2% vs. 5.6%,P < 0.001)。
- M1a患者中,转移灶切除术组中位生存46.36个月,非手术组15.31个月(P < 0.001)。
- 皮肤转移(M1a)接受转移灶切除术的比例高于非M1a转移(34.6% vs. 28.4%,P < 0.001)。
- Cox多因素分析中,所有转移灶切除术患者HR=0.519(P < 0.001,95%CI 0.495-0.545)。
- 亚组分析:M1a HR=0.546(P < 0.001,95%CI 0.456-0.653);M1b HR=0.389(P < 0.001,95%CI 0.328-0.462);M1c HR=0.474(P < 0.001,95%CI 0.434-0.517)。
临床怎么用
- 对于IV期黑色素瘤患者,尤其是皮肤、肺或内脏转移者,可考虑转移灶切除术以改善总生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Current literature supports mixed conclusions regarding the outcomes of metastasectomy in Stage IV melanoma. The objective of this national study was to determine the associations of non-primary site surgery with overall survival (OS) in Stage IV melanoma. METHODS: The National Cancer Database (NCDB) was queried for all Stage IV melanoma cases diagnosed from 2004 to 2015. Cases missing treatment/staging data or undergoing palliative treatment were excluded (remaining n = 14 034). Patients were separated into 'metastasectomy' (n = 4214, 30.0%) and 'non-metastasectomy' (n = 9820, 70.0%) cohorts. Survival outcomes were analysed using Kaplan-Meier and Cox proportional hazards regressions. RESULTS: On univariate analysis, patients with Stage IV melanoma undergoing metastasectomy (median survival: 15.67 month) had greater overall survival compared with those not receiving non-primary surgery (median survival: 7.13 month; 5-year OS 13.2% vs. 5.6%, P < 0.001). M1a patients that underwent non-primary metastasectomy (median survival: 46.36 month) showed greater survival than those that did not (median survival: 15.31 month; P < 0.001). Metastasectomy was undertaken more frequently for cutaneous (M1a) metastasis compared with non-M1a metastasis (34.6% vs. 28.4%, P < 0.001). Of those receiving metastasectomy, 20.3% also received primary site resection, 33.6% radiation, 26.5% chemotherapy and 31.5% immunotherapy. Controlling for covariates on Cox proportional hazard analysis, all metastasectomy patients demonstrated longer survival [Hazard Ratio = 0.519, P < 0.001; CI 95% (0.495-0.545)] as well as when analysing solely M1a metastasectomy patients [Hazard Ratio = 0.546, P < 0.001; CI 95% (0.456-0.653)], lung (M1b) metastasectomy patients [Hazard Ratio = 0.389, P < 0.001; CI 95% (0.328-0.462)] and visceral (M1c) metastasectomy patients [Hazard Ratio = 0.474, P < 0.001; CI 95% (0.434-0.517)]. CONCLUSION: Metastasectomy for Stage IV melanoma is independently associated with improved OS in metastatic cases involving the skin, lung and visceral organs.
引用
- Elias ML, Behbahani S, Maddukuri S, et al. Prolonged overall survival following metastasectomy in stage IV melanoma. J Eur Acad Dermatol Venereol. 2019. PMID: 31070816. doi:10.1111/jdv.15667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。